HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Teva Intelligence Report

Intelligence report

Intelligence Report · ~12 min read

Teva Intelligence Report

Generated from 34 signals · 4 evidence sources

Type

Company Intelligence Report

Generated

Aug 5, 2026

Confidence

Moderate Confidence · 72%

Evidence

201 items

Sources

30

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Teva maintains an active intelligence profile across Anesthesia, Neuromuscular Blockade, Oncology, Small Molecule, Cardiology. 34 signals are linked with 0 investigate-priority items requiring leadership attention. Competitive pressure is low with high portfolio impact. Evidence coverage stands at 72% across 4 tracked sources. Highest-priority development: FDA AP — MYCOPHENOLATE SODIUM (SUPPL). Regulatory precedent. Why this matters: sets a safety guidance precedent in the same sub-indication (nmus rehab) as Teva; the same agency is already in play for this signal, so precedent weight is higher.

Key Developments

Material intelligence events ranked by strategic relevance.

  1. regulatory

    FDA AP — MYCOPHENOLATE SODIUM (SUPPL)

    Regulatory precedent may inform portfolio positioning

  2. regulatory

    FDA AP — ARGATROBAN IN 0.9% SODIUM CHLORIDE (SUPPL)

    Regulatory precedent may inform portfolio positioning

  3. regulatory

    FDA AP — SUGAMMADEX SODIUM (ORIG)

    Regulatory precedent may inform portfolio positioning

  4. regulatory

    FDA AP — SUGAMMADEX SODIUM (ORIG)

    Regulatory precedent may inform portfolio positioning

  5. regulatory

    FDA AP — SUGAMMADEX SODIUM (ORIG)

    Regulatory precedent may inform portfolio positioning

  6. regulatory

    Pratik Doshi, M.D. / Alembic Pharmaceuticals Ltd. - 731020 - 07/10/2026

    Regulatory precedent may inform portfolio positioning

    View detail
  7. regulatory

    Centaur Pharmaceuticals Private Ltd. - 651080 - 06/05/2023

    Regulatory precedent may inform portfolio positioning

    View detail
  8. regulatory

    Centaur Pharmaceuticals Private Ltd. - 651080 - 12/03/2025

    Regulatory precedent may inform portfolio positioning

    View detail
  9. regulatory

    Form FDA 3674 - Certifications To Accompany Drug, Biological Product, and Device Applications/Submissions

    Regulatory precedent may inform portfolio positioning

    View detail
  10. regulatory

    S9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and Answers

    Regulatory precedent may inform portfolio positioning

    View detail
  11. regulatory

    FDA AP — BAXFENDY (ORIG)

    Regulatory precedent may inform portfolio positioning

    View detail
  12. regulatory

    Domperidone: new contraindication in patients with phaeochromocytoma due to the risk of severe hypertension

    Regulatory precedent may inform portfolio positioning

    View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Opportunity score 5510 with buyer quality 4 (Low Priority). Competitive pressure: Low. Portfolio impact: High.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

  • FDA AP — MYCOPHENOLATE SODIUM (SUPPL)

    Moderate Confidence · 77%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — ARGATROBAN IN 0.9% SODIUM CHLORIDE (SUPPL)

    Moderate Confidence · 77%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — SUGAMMADEX SODIUM (ORIG)

    Moderate Confidence · 77%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — SUGAMMADEX SODIUM (ORIG)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — SUGAMMADEX SODIUM (ORIG)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Pratik Doshi, M.D. / Alembic Pharmaceuticals Ltd. - 731020 - 07/10/2026

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Centaur Pharmaceuticals Private Ltd. - 651080 - 06/05/2023

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Centaur Pharmaceuticals Private Ltd. - 651080 - 12/03/2025

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Form FDA 3674 - Certifications To Accompany Drug, Biological Product, and Device Applications/Submissions

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • S9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and Answers

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — BAXFENDY (ORIG)

    Moderate Confidence · 77%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Domperidone: new contraindication in patients with phaeochromocytoma due to the risk of severe hypertension

    Low Confidence · 54%

    Regulatory precedent may inform portfolio positioning

    Source: MHRA, MHRA, Regunera

    View evidence

  • FDA approves palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of HR-positive, HER2-positive metastatic breast cancer

    High Confidence · 95%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA Approves First Generics of Gilotrif (afatinib) Tablets

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA approves pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph each with enfortumab vedotin-ejfv for muscle invasive bladder cancer

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • FDA Grants Approval for Macitentan ANDA211187 by Teva Pharmaceuticals

    Cardiology · Pulmonary Arterial Hypertension

  • Teva's Budesonide and Formoterol Fumarate Dihydrate Receives FDA Approval

    Respiratory · Asthma/COPD

  • FDA Grants Approval for Glycerol Phenylbutyrate by Teva Pharmaceuticals

    Metabolic Disorders · Urea Cycle Disorders

  • FDA Approves Supplemental Application for Copaxone (Glatiramer Acetate)

    Neurology · Multiple Sclerosis

  • Teva's Sugammadex Sodium Receives FDA Approval Status

    Anesthesia · Neuromuscular Blockade

  • FDA Approves Supplemental NDA for ZIAC by Teva

    Cardiovascular · Hypertension

  • Teva's Gabapentin ANDA205807 Receives Approval Status from FDA

    Neurology · Anticonvulsant

  • FDA Approves Supplemental Application for AJOVY (Fremanezumab)

    Neurology · Migraine

PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.